Article Sidebar
Views PDF: 203
SURVIVAL TIME OF DOCETAXEL PLUS TRASTUZUMAB AS THE FIRST-LINE IN PATIENTS WITH RECURRENT OR METASTATIC HER2-POSITIVE BREAST CANCER
Main Article Content
Abstract
Objectives: Evaluation of progression-free survival time of patients with docetaxel plus trastuzumab as the first-line in patients with recurrent or metastatic HER2-positive breast cancer. Patients and methods: A retrospective and prospective descriptive study on 56 patients diagnosed with HER2-positive metastatic or recurrent breast cancer at K Hospital from January 2015 to October 2022. Result: The mean age was 53.1±14.3 years. Median progression-free survival was 13 months. Progression-free survival at 6 months and 12 months were 80.4% and 51.8%, respectively. Patients without visceral metastasis had a higher median PFS than the visceral metastasis patients (14.0 months vs 8.0 months; p=0.011). No correlation was found between PFS and factors such as ECOG, histopathology, endocrine receptor status, and adjuvant chemotherapy (taxane versus no taxane; trastuzumab versus no trastuzumab). Conclusion: Docetaxel plus trastuzumab as the first-line is effective in high progression-free survival for patients with recurrent or metastatic of HER2-positive breast cancer.
Article Details
Keywords
Docetaxel, recurrent or metastatic breast cancer, trastuzumab.
References
2. Sato N, Sano M, Tabei T, et al: Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, Phase-II study. Breast Cancer 13, 166–171 (2006).
3. Raab G, Brugger W, Harbeck N, et al: Multicenter randomized Phase II study of docetaxel (Doc) given q3w vs. q1w plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracycline pretreated metastatic breast cancer (MBC). Breast Cancer Res. Treat. 76, S114 (2002)
4. Tedesco KL, Thor AD, Johnson DH, et al: Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional Phase II trial. J. Clin. Oncol. 22, 1071–1077 (2004).
5. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(19):4265-4274.
6. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(18):2786-2792.
7. Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol Off J Am Soc Clin Oncol. 2011; 29(2):149-156.
8. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
9. Perez EA, Suman VJ, Rowland KM, et al: Two concurrent phase II trials of paclitaxel/carboplatin/ trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 6:425-432, 2005
10. Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer. 2005;6(3):247-252.